148 related articles for article (PubMed ID: 30349988)
1. Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.
van Kuilenburg ABP; Meijer J; Meinsma R; Pérez-Dueñas B; Alders M; Bhuiyan ZA; Artuch R; Hennekam RCM
JIMD Rep; 2019; 45():65-69. PubMed ID: 30349988
[TBL] [Abstract][Full Text] [Related]
2. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
[TBL] [Abstract][Full Text] [Related]
3. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
5. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
6. Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.
van Kuilenburg AB; Meijer J; Gökcay G; Baykal T; Rubio-Gozalbo ME; Mul AN; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Roelofsen J; Vijzelaar R; Nicolai J; Hennekam RC
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):509-14. PubMed ID: 20544545
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin.
Fernandez-Salguero PM; Sapone A; Wei X; Holt JR; Jones S; Idle JR; Gonzalez FJ
Pharmacogenetics; 1997 Apr; 7(2):161-3. PubMed ID: 9170156
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype?
Fleger M; Willomitzer J; Meinsma R; Alders M; Meijer J; Hennekam RCM; Huemer M; van Kuilenburg ABP
JIMD Rep; 2017; 37():49-54. PubMed ID: 28275972
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
Au KM; Lai CK; Yuen YP; Shek CC; Lam CW; Chan AY
Hong Kong Med J; 2003 Apr; 9(2):130-2. PubMed ID: 12668826
[TBL] [Abstract][Full Text] [Related]
11. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
van Kuilenburg AB; Meijer J; Mul AN; Hennekam RC; Hoovers JM; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Vijzelaar R; Nicolai J; Ylstra B; Rubio-Gozalbo ME
Hum Genet; 2009 Jun; 125(5-6):581-90. PubMed ID: 19296131
[TBL] [Abstract][Full Text] [Related]
12. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient.
Mazur A; Figurski S; Płoskoń A; Meijer J; Zoetekouw L; Watróbska S; Sykut-Cegielska J; Gradowska W; van Kuilenburg AB
Acta Biochim Pol; 2008; 55(4):787-90. PubMed ID: 19081848
[TBL] [Abstract][Full Text] [Related]
14. Dihydropyrimidine dehydrogenase deficiency in two malaysian siblings with abnormal MRI findings.
Chen BC; Mohd Rawi R; Meinsma R; Meijer J; Hennekam RC; van Kuilenburg AB
Mol Syndromol; 2014 Dec; 5(6):299-303. PubMed ID: 25565930
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
16. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.
van Kuilenburg AB; Dobritzsch D; Meinsma R; Haasjes J; Waterham HR; Nowaczyk MJ; Maropoulos GD; Hein G; Kalhoff H; Kirk JM; Baaske H; Aukett A; Duley JA; Ward KP; Lindqvist Y; van Gennip AH
Biochem J; 2002 May; 364(Pt 1):157-63. PubMed ID: 11988088
[TBL] [Abstract][Full Text] [Related]
17. Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
van Kuilenburg ABP; Tarailo-Graovac M; Meijer J; Drogemoller B; Vockley J; Maurer D; Dobritzsch D; Ross CJ; Wasserman W; Meinsma R; Zoetekouw L; van Karnebeek CDM
Hum Mutat; 2018 Jul; 39(7):947-953. PubMed ID: 29691939
[TBL] [Abstract][Full Text] [Related]
18. Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.
Khushman M; Patel GK; Hosein PJ; Laurini JA; Cameron D; Clarkson DR; Butler TW; Norden CW; Baliem W; Jones V; Bhadkamkar S; Nelson C; Lee F; Singh AP; Taylor WR
J Gastrointest Oncol; 2018 Jun; 9(3):416-424. PubMed ID: 29998006
[TBL] [Abstract][Full Text] [Related]
19. FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).
Hormozian F; Schmitt JG; Sagulenko E; Schwab M; Savelyeva L
Cancer Lett; 2007 Feb; 246(1-2):82-91. PubMed ID: 16556484
[TBL] [Abstract][Full Text] [Related]
20. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
